Soluble truncated ERBB-ECD can be measured in the serum fraction of blood, which is related to the outcome of HER2-positive breast cancer and sensitivity to some treatments [15,16,17,18,19,20,21]. This evidence concerns the gene ERBB2 and breast cancer.